Thirty-two patients with chronic hepatitis who were positive for hepatitis C virus (HCV) RNA by polymerase chain reaction and had antibody to HCV (anti-HCV), were enrolled in this study. Twenty oUhem were also positive for antibody to the GOR epitope (anti-GOR). Sixteen of the enrolled patients were treated with human Iymphoblastoid interferon for six months. Treatment was initiated with 3 million units of interferon daily for 2 weeks, followed by 3 million units three times a week for 6 weeks and 1.5 million units three times a week for 16 weeks. The efficacy of therapy was assessed by comparison with the results in 16 untreated patients. Aminotransferase values, titre of anti-HCV and anti-GOR antibodies showed significant decreases throughout the therapy compared with baseline levels and the untreated patients. After a 3 month follow-up, nine treated patients (56.3%) had normal aminotransferase activities and six of them eliminated HCV RNA from their sera (37.5%). Three of these six patients became negative for both anti-HCV and anti-GOR antibodies (18.8%). None of the untreated control patients had normal aminotransferase activities or became negative for HCV markers. The present study suggests that human Iymphoblastoid interferon can control the disease activity and eliminate hepatitis C virus from patients with chronic hepatitis C. Received 
Introduction
Non-A, non-B hepatitis is a common and a major cause of liver disease. It has recently been shown that the majority of patients with parenterally acquired non-A, non-B hepatitis show evidence of infection with an RNA virus that is now referred to as the hepatitis C virus (HCV) (Bruix et al., 1989; Choo et al., 1989; Kuo et al., 1989; Van der Poel et al., 1900) . It has been established that non-A, non-B hepatitis is responsible for over 90% of cases of posttransfusion hepatitis (Dienstag et al., 1977) and is associated with 20-50% of the incidence of chronic liver disease in developed countries (Koretz et al., 1976) . Hoofnagle et al. (1986) observed a marked reduction in serum aminotransferase levels in eight of 10 patients with non-A, non-B chronic hepatitis treated with recombinant leukocyte interferon alpha. Other investigators have reported that interferon therapy produced beneficial effects in patients with non-A, non-B chronic hepatitis (Davis et al., 1989; Di Bisceglie et al., 1989; Omata et al., 1989; Kakumu et al., 1990; Nakano et al., 1990) . They found that interferon effectively reduced serum aminotransfer ase levels and hepatocellular necrosis in cases of chronic non-A, non-B hepatitis. As the antiviral effect was not mentioned, we treated patients with chronic hepatitis C with human Iymphoblastoid interferon (HLBI) to evaluate the antiviral effects of the interferon as well as its clinical efficacy.
Results
The principal side effects of HLBI are fatigue, fever, anorexia, and mild, reversible hair loss. These tend to be at their worst during the first week. Fatigue is particularly noticeable, but most patients are able to maintain a normal work schedule.
Serial determinations of alanine aminotransferase (AL1) values in the 16 treated patients showed that significant decreases in ALT values began 4 weeks after the start of treatment and were usually sustained for as long as the interferon therapy was continued. Once the therapy was discontinued, mean ALT levels tended to increase. Of the 16 patients, ALT values fell to within a normal range in 11 patients (68.8%) at the termination of the therapy, and in four of these patients, the enzyme levels were subsequently elevated. Two other patients, in whom the ALT was not normalized at the end of therapy, fell into the ALT-norrnalized group with gradual decreases of ALT during the follow-up period. Thus, nine patients (56.3%) comprised the ALT-normalized group and the remaining seven patients (43.8%) the ALT-non-normalized group. The serum ALT value did not normalize in any untreated patient along with elevated ALT. The titre of anti-HCV antibody of this patient was elevated compared to that before treatment. An elevated titre of anti-HCV antibody was found in six patients including this one during the follow-up period (Fig. 2) . The titre of antibody to the GOR epitope (anti-GOR) decreased in eight (80%) of the 10 seropositive patients treated ( Fig. 3 ). Three patients (30%) became both negative for anti-GOR and anti-HCV during the follow-up period. Two of them became negative for anti-HCV simultaneously and the remaining patient became seronegative subsequent to becoming anti-HCV-negative. 
Discussion
The significance of HCV infection among subjects with non-A, non-B hepatitis has been revealed by the development of an ELISA assay for anti-HCV antibody (Bruix et al., 1989; Choo et al., 1989; Kuo et aI., 1989; Van der Poel et aI., 1989; Hayashi et sl., 1991) . Patients with chronic HCV RNA was eliminated from the sera of six patients (Table 1 ). In all of these patients aminotransferase was persistently normalized during observation. Three of them also became negative for both anti-HCV and anti-GOR antibodies. The remaining three patients were persistently positive for anti-HCV antibody, but its titre decreased during observation. In the untreated patients, the titre of anti-HCV and anti-GOR antibodies neither decreased nor disappeared, and HCV RNA was not eliminated during the 24 weeks of observation.
Pretreatment factors (sex, age, ALT value, anti-GOR status) of ALT-normalized (nine patients) and non-normalized (seven patients) groups were compared. There were no statistically significant differences between the two groups ( Table 2) . during the 36 weeks of observation. Therefore, there were significant differences in the mean ALT levels between the treated and untreated groups throughout the therapy ( Fig.   1 ).
A significant reduction in antibody to HCV (anti-HCV) titre occurred by the end of treatment, as compared with pretreatment levels. The titre of anti-HCV antibody decreased in 15 (93.8%) of 16 treated patients, but was elevated in six of these 15 patients during the 3-month follow-up period. Four patients (25%) who had shown relatively low titres of anti-HCV antibody before interferon treatment became seronegative after the treatment. Anti-HCV reappeared in one patient during the follow-up period Fig. 1 . Serial results of alanine aminotransferase (ALT) levels (mean ± SE) in 16 patients with chronic hepatitis C who were treated with human lyrnphoblastoid interferon (3 million units daily for 2 weeks, 3 million units per day, thrice weekly for 6 weeks, 1.5 million units per day, thrice weekly for 16 weeks) and in 16 patients who did not receive the therapy.
Differences in ALT levels were analysed using x 2 test with Yates correction. hepatitis C have been found to develop liver cirrhosis and hepatocellular carcinoma (Kiyosawa et aI., 1990) . Although HBV infection is endemic in Japan (Kashiwagi et al., 1983) , chronic liver disease caused by HCV is apparently more common than that caused by HBV (Hayashi et al., 1991b; Nishioka et al., 1991) . We have also noted that the prevalence of anti-HCV increased with the degree of severity of liver disease (Hayashi et al., 1991b) .
In 1976, Greenberg et al. (1976) reported that interferon could serve as a treatment for patients with chronic hepatitis B. As antiviral agents alone do not inhibit the replication of HBV, efforts have been made to improve the therapeutic effect of interferon for chronic hepatitis B by combining interferon with immunosuppressive or antiviral drugs (Omata & Uchiumi, 1983; Hayashi et al., 1991b; Schalm, 1985) . In contrast, treatment with interferon led to Interleron therapy and hepatitis C 307 a rapid biochemical resolution in chronic non-A, non-B hepatitis (Davis et al., 1989; Di Bisceglie et al., 1989; Omata et aI., 1989; Kakumu et al., 1990) . The optimal dose and duration of administration remains unclear.
Our patients with chronic HCV infection were treated with natural interferon alpha for 24 weeks. Davis et al. (1989) and Causse et al. (1991) reported that 3MU was more effective than 1 MU. Kakumu et al. (1990) also suggested that 4MU was more effective than 2MU. Jacyna et al. (1989) reported that intermlttent therapy with continuous low-dose interferon reduced the aminotransferase activity to normal in most patients with non-A, non-B hepatitis. Thus, intermittent administration of lowdose interferon for a prolonged period of time may be the first step in optimizing the conditions for interferon therapy. The results were obtained after 12-18 months of treatment with interferon (Ferenci et al., 1990; Gomez-Rubio et aI., 1990) . Following this rationale, our patients were first given 3 MU then 3 MU-1.5 MU for 6 months.
The titre of anti-HCV antibody during treatment decreased in almost all the treated patients, while that in all untreated patients was unchanged. Changes in anti-HCV antibody titre revealed the antiviral effect of interferon. Because three patients who became seronegative initially had a low titre of anti-HCV antibody, patients with a high titre of anti-HCV antibody may need a higher dose and a longer duration of interferon therapy. Testing for anti-HCV antibody titre may be useful in determining the optimal dose of interferon. An epitope with a particular amino acid sequence (GOR epitope) has been isolated from the plasma of a chimpanzee infected with human non-A, non-B hepatitis agent. An ELISA test was developed for antibodies to the GOR epitope, and the circulating HCV RNA can be detected by PCR in most patients seropositive for anti-GOR but negative for anti-HCV antibodies (Mishiro et aI., 1990) . Anti-GOR antibody is one of the markers of HCV infection. The titre of anti-GOR antibody also decreased in 80% of patients after treatment with interferon, as did anti-HCV antibodies. This result suggests that if one of the two antibodies disappears, the remaining antibody might also disappear. Also all three patients who became negative for anti-HCV antibody after a 3 month follow-up period were initially positive for anti-GOR. It is interesting that HCV RNA was eliminated from the sera of three treated patients in spite of their being anti HCV-positive. We speculate that, anti-HCV antibody may disappear in these patients because the titre of anti-HCV gradually decreased during the observation period. It seems that HCV RNA is the most useful marker of the antiviral effect of interferon therapy. Moreover, detection of HCV RNA by polymerase chain reaction (PCR) may serve as a marker for the discontinuation of interferon administration.
Two patients Who were positive for both anti-HCV and HBsAg were anti-HBe-positive, HBV DNA polymerasenegative and anti-HDV-negative. Because they were negative for HBV replicative markers, HCV may have played a leading role in causing chronic hepatitis (Fattorich et al., 1979) . This regimen was effective for one of these patients. If HBV is not replicative, the objective of interferon therapy in patients with dual infections is to suppress the HCV.
Our study shows that long term administration of HLBI can control disease activities and eliminate HCV RNA from patients with chronic hepatitis C.
Materials and Experimental procedures

Patients
Twenty men and 12 women aged 23-62 years with chronic hepatitis C were randomly allocated to either an HLBI treatment (16 patients) or untreated group (16 patients). Nineteen patients had histories of blood transfusion, but none had a history of alcoholism, drug abuse, homosexuality, or haemophilia. Abnormal levels of asparate aminotransferase (AST) and ALThad persisted tor periods ranging from six months to 20 years before the trial was initiated. All these Japanese patients were positive for anti-HCV and 20 were also positive for anti-GOR (Mishiro et al., 1990) . Prior to treatment, HCV RNA was identified by PCR in all serum samples. Three patients were positive for HBsAg, but negative for HBeAg, HBV DNA polymerase and antibody to hepatitis D virus (anti-HDV) for six months. All patients were negative for anti-nuclear antibody, anti-smooth muscle antibody, and anti-mitochondria antibody. Histological diagnosis of liver biopsy specimens revealed chronic persistent hepatitis (CPH) in 13 patients and chronic active hepatitis (CAH) in 19. Data on the patients studied are given in Tables 1 and 2. The two groups were similar with respect to age, sex, known duration of hepatitis, history of blood transfusion, results of liver function test, and liver histology prior to treatment. Patients who had other major problems or who had received immunosuppressants or antiviral therapy within the previous six months were not included in this study.
Protocol
The patients were given intramuscular injections of HLBI (Sumypheron, Sumitomo Co., Tokyo, Japan). A dose of 3 million units (MU) was given daily for 2 weeks, and 3 MU was given three times a week for the next 6 weeks followed by 1.5 MU three times a week for 16 weeks. The total dose given was 168 MU over a 24-week period. Fully informed written consent was obtained from all the treated patients.
Methods
Paired blood samples were obtained every 2 weeks during the therapy, and every 2-4 weeks for at least 3 months before entry and after cessation of the treatment. Each blood sample was tested for complete blood count and routine serum biochemistry. A level of ALT over 40 lUlL was regarded as abnormally high.
The 'Ortho-HCV' ELISA (Ortho Diagnostics, Raritan, NJ, USA) was used to detect anti-HCV antibody. The test was performed according to the manufacturer's instructions.
Anti-GOR antibody were measured by ELISA (Institute of Immunology, Tokyo, Japan).This indirect assay involves use of an epitope with an amino acid sequence GRRGQKAKSNPNRPL (GORepltope) borne by a eDNA clone (GOR47-1) as described in detail by Mishiro et al. (1990) .
The serum samples of 32 patients were tested at the start and end of the observation for genomic RNA of HCV by PCR. The primers used were: 5'-CTGTGAGGAACTACTGTCTT-3' (sense; nt 28-47) and 5'-AACACTACTCGGCTAGCAGT-3' (antisense; nt 229-248) in the first stage, and 5'-TTCACGCAGAAAGCGTCTAG-3' (sense; nt 46-65) and 5'-GTTGATCCAAGAAAGGACCC-3' (antisense; nt 171-190) in the second stage.
HBsAg, HBeAg and anti-HBe were measured by radioimmunoassay (Ausria II, HBeRIA, Abbott Laboratories, North Chicago, IL, USA). HBV DNA polymerase in the sera of HBsAg-positive patients was measured by the method of Kaplan et al. (1977) .
To estimate semi-quantitatively the titre of anti-HCV and anti-GOR antibodies, seropositive sera were serially diluted in saline in two-fold steps. We judged the titre of anti-HCV or anti-GOR antibody for the point of positivity in maximum-dilution (undiluted = 2°, two-fold diluted = 2 1 , four-fold diluted = 2 2 , eight-fold = 2 3 ) .
Statistical analysis
Student's t-test or x 2 test with the Yates correction was used to determine the statistical significance of the data. Variables in the text are expressed as mean ± SE.
